Hot Off the Press: Changes in the Landscape of Multiple Myeloma

Slides:

Advertisements

Similar presentations

Treatment For Newly Diagnosed Myeloma

Advertisements

Should Alkylators be used Upfront in Transplant-Ineligible Patients? NO!! Lymphoma-Myeloma October 2013 Scottsdale, Arizona Rochester, Minnesota Jacksonville,

Ravi Vij MD Associate Professor Section of BMT and Leukemia

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Please note, these are the actual video- recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

1 Changing Patient Care in Multiple Myeloma: The IMF Nurse Leadership Board’s Long-Term Survivorship Care Plan Accredited by Medical Education Resources.

Maintenance Therapy in Myeloma Myeloma Canada National Conference Donna E. Reece, M.D. Princess Margaret Hospital 24 September 2011.

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance.

ASCO 2010 Lenalidomide maintenance after transplantation for myeloma (IFM Study) Authors: Attal et al, ASCO 2010 Abstract:

Proteasome inhibitors in multiple myeloma: 10 years later Philippe Moreau, Paul G. Richardson, Michele Cavo, Robert Z. Orlowski, Jesu´s F. San Miguel,

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management S. Vincent Rajkumar Am. J. Hematol. 88:226–235, R4 신재령.

Multiple Myeloma: Is it now a curable disease?

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

December 3-6, 2016; San Diego, California

MRD testing: which platforms, which patients?

Editor: Neil Love, MD Faculty commentator: Noopur Raje, MD

Relapsed / Refractory Multiple Myeloma

Myeloma hope new treatment in the horizon

MRA Clinical Trials Day Myeloma UK Clinical Trial Network

Palumbo A et al. Proc ASH 2012;Abstract 200.

ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM

Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS) in September 2015 She has been monitored.

Attal M et al. Proc ASH 2010;Abstract 310.

December 7-10, 2013 New Orleans, Louisiana

Andrzej Jakubowiak Seminars in Hematology

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

Nurses' Toolbox: How to Improve Patient Outcomes in Multiple Myeloma

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Improving Survival in Glioblastoma Multiforme

Challenging Cases in Multiple Myeloma Panel Discussion

Targeting FLT3 Mutations in Acute Myeloid Leukemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Innovations and Issues in Mantle Cell Lymphoma

Relapsed/Refractory Follicular Lymphoma Conundrums

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis Meletios Athanasios.

Selecting Therapy for Relapsed/ Refractory Multiple Myeloma

James R. Berenson, MD Medical & Scientific Director

Updates in Management of Atopic Dermatitis From Real Patient Cases

Multiple Myeloma: Diagnosis and Treatment

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

Selecting MM Therapy in Patients With Comorbidities

The Nurse View: Best Practices in Multiple Myeloma

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Multiple Myeloma

Optimizing Frontline Care for Older Patients With Multiple Myeloma

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

Advances in Multiple Myeloma: Data Highlights and Analysis from the 2015 Hematology/Oncology Conferences.

Approaches in Newly Diagnosed Multiple Myeloma: When and What

Staying Abreast of Best Practices Across the Clinical Continuum

New Classes of Therapy in Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

The Role of Maintenance Therapy in Multiple Myeloma

Proteasome Inhibitors and Patients

On the Cusp: New Approaches for Multiple Myeloma

Phase III MAIA: Daratumumab + Len/Dex vs Len/Dex in Transplantation-Ineligible Newly Diagnosed Multiple Myeloma Integrating New Malignant Hematology Findings.

Diagnosis of Multiple Myeloma

Renal Function and Myeloma Therapeutics

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Spotlight on Monoclonal Antibodies in Multiple Myeloma

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

Maintenance therapies in Multiple Myeloma

Presentation transcript:

Hot Off the Press: Changes in the Landscape of Multiple Myeloma

Program Goals

Outline

Diagnostic Criteria Multiple Myeloma Requiring Therapy

PFS and OS According to the R-ISS

Validation of the R-ISS

Selecting Therapy

Newly Diagnosed Multiple Myeloma Primary Induction for SCT Candidates

IFM 2013-04 VTD vs CyBorD in Newly Diagnosed MM

SWOG S0777 VRd vs Rd

Induction Therapy Conclusions

ASCT

STaMINA Trial BMT CTN 0702

Patients Ineligible for ASCT

FIRST Trial Continuous Rd vs Rd-18 vs MPT

Modified Lenalidomide, Bortezomib, and Dexamethasone

Consolidation and Maintenance

Lenalidomide Maintenance After ASCT A Meta-Analysis

Relapsed/Refractory MM

Agents Approved for R/R MM in 2015

ASPIRE KRd vs Rd

TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

ENDEAVOR Kd vs Vd

ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

Two Large Randomized Studies of Daratumumab Reported in 2016

CASTOR Study Daratumumab + Bor/Dex vs Bor/Dex

POLLUX Study Daratumumab + Len/Dex vs Len/Dex

Case

Considerations for Case

Select Emerging Agents in MM

Key Takeaways

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)